Chemotherapy Duration in Metastatic Disease

General Principles

The National Comprehensive Cancer Network recommends that chemotherapy in metastatic disease should generally continue until disease progression or unacceptable toxicity, not for a predetermined fixed duration, though maintenance strategies with reduced-intensity regimens are preferred over continuous full-dose combination therapy 1
First-line platinum-based combination chemotherapy should be limited to 4-6 cycles, as extending beyond this provides no additional survival benefit and increases toxicity 1, 2
After initial combination therapy, maintenance strategies are superior to both observation and continuing full-dose combination chemotherapy 1, 2

For metastatic breast cancer, the National Comprehensive Cancer Network recommends continuing first-line regimens until progression or unacceptable toxicity as the standard approach, with sequential monotherapy preferred over combination therapy except when rapid disease control is needed 1
In metastatic colorectal cancer, initial combination chemotherapy for 3-6 months followed by maintenance therapy is the optimal strategy, with maintenance with fluoropyrimidine ± bevacizumab prolonging progression-free survival compared to complete treatment breaks 3, 4
For non-small cell lung cancer, platinum-doublet chemotherapy should be limited to 4-6 cycles, with continuation maintenance with pemetrexed or switch maintenance with erlotinib showing progression-free and overall survival benefits 2
In metastatic bladder cancer, platinum-based chemotherapy continues until progression, unacceptable toxicity, or patient refusal, with checkpoint inhibitors continuing until progression when used in appropriate settings 6, 7

Unacceptable toxicity requiring cessation of chemotherapy includes cumulative toxicity preventing adequate quality of life, grade 3-4 toxicities that persist despite dose modifications, and patient preference after informed discussion of risks versus benefits 1, 3, 6
Disease progression mandates switching to second-line therapy using a different mechanism of action, re-evaluation of performance status to determine eligibility for further treatment, and consideration of clinical trial enrollment for subsequent lines 1, 2, 3, 8